8 th European Lung Cancer Congress (ELCC) Geneva, Switzerland, April 2018 PROGRAMME. Wednesday, 11 April Industry Satellite Symposium 1

Size: px

Start display at page:

Download "8 th European Lung Cancer Congress (ELCC) Geneva, Switzerland, April 2018 PROGRAMME. Wednesday, 11 April Industry Satellite Symposium 1"

Kory Nash
5 years ago
Views:

1 8 th European Lung Cancer Congress (ELCC) Geneva, Switzerland, April 2018 PROGRAMME Wednesday, 11 April :00-13:00 13:00-13:30 Hall 1 Industry Satellite Symposium 1 Welcome Reception 13:30-13:45 Opening and welcome Room B 15 Welcome to the Congress 13:45-14:15 Keynote lecture Room B HHH Award lecture 30 HHH Award lecture To be announced 14:30-16:00 Educational session Room B First line for oncogene addicted lung cancer 20 Is PFS still a relevant endpoint for first-line TKIs? Suresh Ramalingam, Atlanta, GA, US 20 First vs second vs third generation EGFR TKI Juergen Wolf, Cologne, DE 20 Key factors that determine the selection of firstline Fiona Blackhall, Manchester, UK ALK inhibtiors 20 The role of first-line combination therapy for Takashi Seto, Fukuoka, JP oncogene addicted lung cancer 14:30-16:00 Educational session Combined treatment stage III 20 When concurrent chemo-radiotherapy is not the preferred choice 20 Are current NTCP models useful for predicting radiation-induced toxicity? 20 Surgical salvage of recurrences following CT-RT: Indications and outcomes 20 Immunotherapy in the stage III paradigm: Rationale and clinical data Pierre Fournel, Saint-Priest-en-Jarez, FR Dirk De Ruysscher, Maastricht, NL Chris Dickhoff, Amsterdam, NL Solange Peters, Lausanne, CH 16:00-16:30 Coffee break 1

2 Wednesday, 11 April 2018 cont. 16:30-18:00 Educational session Room B First line for non-oncogene addicted lung cancer 20 First-line chemotherapy in NSCLC: Where do we stand? 20 Immunotherapy in the first-line setting: What have we achieved? 20 First-line therapy in PS2 and elderly patients: Any new signals? 20 First-line therapy: What might we expect for the future? Rolf A. Stahel, Zurich, CH Martin Reck, Grosshansdorf, DE Elisabeth Quoix, Strasbourg, FR Giorgio Scagliotti, Turin, IT 16:30-18:00 Educational session Early stage NSCLC: Where do we stand in 2018? 20 Guidelines for surgery in ground glass opacities Kenji Suzuki, Tokyo, JP 20 Pathology and biomarkers in resected NSCLC Elisabeth Brambilla, Grenoble, FR 20 Neoadjuvant immunotherapy in early-stage NSCLC Patrick Forde, Baltimore, MD, US 20 Stereotactic radiotherapy for early stage NSCLC Shankar Siva, Melbourne, AU 18:30-20:00 Industry Satellite Symposium 2 Thursday, 12 April :00-08:50 Multidisciplinary Interactive Session (MIS) Management of CT detected small nodules 15 Controls and timeline in the presence (or not) of small pulmonary nodules detected during lung cancer screening 15 Surgical management of small pulmonary nodules detected during lung cancer screening 20 Discussion 08:00-08:50 Multidisciplinary Interactive Session (MIS) Room W Management of oligometastatic disease 15 Evolving role of radiation therapy in oligometastatic disease: Beyond brain and lung stereotactic radiotherapy 15 Is it possible to improve patients outcome in oligometastatic NSCLC with local therapy? 20 Discussion Speakers Mamta Ruparel, London, UK Alessandro Brunelli, Leeds, UK Speakers Matthias Guckenberger, Zurich, CH Ramon Rami-Porta, Terrassa, ES 09:00-10:30 Educational session Room B Second line in non-oncogene addiction 20 Chemotherapy combined with antiangiogenics: Marina Garassino, Milan, IT Which patients and when? 20 Immunotherapy: Which patients and when? Edward Garon, Los Angeles, CA, US 20 Hyperprogressive disease in second-line Benjamin Besse, Villejuif, FR 20 New promising strategies in second-line Roy S. Herbst, New Haven, CT, US 2

3 Thursday, 12 April 2018 cont. 09:00-10:30 Young Oncologist session PART ONE - Oligometastatic NSCLC 15 Management of oligometastatic NSCLC with driver mutations 15 Clinical case from a young oncologist with oligometastatic NSCLC pt with driver mutations 15 Q&A / Discussion PART TWO Lung cancer for young oncologists 15 How to prepare a relevant clinically-based project in lung cancer 15 The importance of mentorship in the European environment 15 Q&A / Discussion 09:15-10:15 Controversy session Uncommon driver alterations: Should we use offlabel targeted agents? 10 Introduction and first vote 20 Follow guidelines of non oncogene addicted NSCLC 20 Give an off-label prescription based on the best knowledge 10 Second vote and conclusions Raffaele Califano, Manchester, UK To be announced Luis Paz-Ares, Madrid, ES Rolf A. Stahel, Zurich, CH Fortunato Ciardiello, Naples, IT Julien Mazières, Toulouse, FR 10:30-11:00 Coffee break 11:00-12:30 Specialty session Developments in pharmacology for systemic therapy 20 Pharmacokinetics and interaction for TKI Sanjay Popat, London, UK treatment 20 Dosing and scheduling of monoclonal antibodies Timothy Yap, Houston, TX, US 20 Target treatment combinations: Rationale and David Carbone, Columbus, OH, US evidence 20 Interactions of immunotherapy with other Stéphane Champiat, Paris, FR therapies / Panel Discussion 11:00-12:30 Specialty session State of the art of PD-L1 testing 20 Choosing PD-L1 assay(s) for a pathology lab Keith Kerr, Aberdeen, UK 20 Establishing PD-L1 laboratory developed assay Sylvie Lantuejoul, Lyon, FR 20 Automation in PD-L1 analysis David L. Rimm, New Haven, CT, US 20 Clinical reporting of PD-L1 test results John R. Gosney, Liverpool, UK / Panel Discussion 3

4 Thursday, 12 April 2018 cont. 11:00-12:30 Specialty session Room W Advances in surgery 20 The relevance of pre-resection transcervical Sergi Call, Terrassa, ES lymphadenectomy in lung cancer 20 Present indications of wedge resections and Hisao Asamura, Tokyo, JP segmentectomy in lung cancer: Any clues from the ongoing clinical trials? 20 Why it is important to keep the Residual Tumour John Edwards, Sheffield, UK (R) descriptor after ptnm: Results from the analyses of the IASLC database 20 Resection of progressive disease after SBRT Paul Van Schil, Edegem, BE / Panel Discussion 11:00-12:30 Specialty session Room X Advances in radiation 20 Stereotactic radiotherapy (SBRT/SABR): state of Françoise Mornex, Lyon, FR the art in MRI guided radiation therapy Suresh Senan, Amsterdam, NL 20 Role of proton therapy for lung cancer Jefrey Bradley, St. Louis, MO, US 20 Role of carbon therapy for lung cancer Yuko Nakayama, Yokohama, JP / Panel Discussion 12:30-13:00 Poster lunch 13:00-14:00 Industry Satellite Symposium 3 14:10-14:40 Room B Keynote lecture Chair: 30 Molecular and immuno landscaping in lung cancer Maria Sibilia, Vienna, AT 14:45-16:15 Educational session Relevant biomarkers for the use of immune checkpoints 15 Update on PD-L1 and other Fred R. Hirsch, Denver, CO, US immunohistochemistry biomarkers 15 Can we use cytology specimens for PD-L1 testing? Lukas Bubendorf, Basel, CH 15 Comprehensive profiling of the immune Ignacio Wistuba, Houston, TX, US microenvironment 15 Molecular profiling Reinhard Büttner, Cologne, DE 30 Q&A 15:00-16:00 Controversy session T790M: Liquid biopsy or histological samples? 10 Introduction and first vote 20 Liquid biopsy Noemi Reguart, Barcelona, ES 20 Histological samples Etienne Rouleau, Villejuif, FR 10 Second vote and conclusions 16:15-16:45 Coffee break 4

5 Thursday, 12 April 2018 cont. 16:45-18:15 Educational session How can we optimise our organisation to deliver precision oncology? 20 Organisational models for biomarkers testing Sanjay Popat, London, UK 20 Access to personalised medicine Pilar Garrido, Madrid, ES 20 The pathologist s point of view Fernando Lopez Rios, Madrid, ES 20 The patient s point of view Silvia Novello, Orbassano, IT 18:40-19:40 18:40-19:40 Industry Satellite Symposium 4 Industry Satellite Symposium 5 Friday, 13 April :00-08:50 Multidisciplinary Interactive Session (MIS) Combining radiation with non-chemotherapy agents 15 Combining radiotherapy with TKIs in oligoprogressive oncogene addicted NSCLC 15 Combining radiotherapy with immune-checkpoint inhibitors 20 Discussion Speakers Nicolaus Andratschke, Zurich, CH Aung Naing, Houston, TX, US 08:00-08:50 Room W Multidisciplinary Interactive Session (MIS) Liquid biopsy at the initial diagnosis and during monitoring 5 Speakers 15 Which technology can we use? CTCs vs ctdna Marc Denis, Nantes, FR 15 Diagnosis and monitoring with liquid biopsy for Fabrice Barlesi, Marseille, FR targeted treatment 20 Discussion 09:00-10:30 Educational session Room B Immunotherapy combinations 20 Immunotherapy and chemotherapy combinations Santiago Ponce Aix, Madrid, ES 20 Combination of immunotherapy with targeted Lizza Hendriks, Maastricht, NL therapies 20 Combination of immunotherapies Scott Antonia, Tampa, FL, US 20 Combination of immunotherapy with radiation Hak Choy, Dallas, TX, US therapy 09:15-10:15 Controversy session Next generation TKI: Front line or later? 10 Introduction and first vote 20 Front line Raffaele Califano, Manchester, UK 20 Later Egbert Smit, Amsterdam, NL 10 Second vote and conclusions

6 Friday, 13 April 2018 cont. 10:30-11:00 Coffee break 11:00-12:30 Educational session Room B Resistance to TKIs 20 General mechanisms of resistance Tetsuya Mitsudomi, Osaka, JP 20 Therapeutic strategies to overcome EGFR Tony S.K. Mok, Hong Kong, CN 20 Therapeutic strategies to overcome ALK and ROS1 Sandra Ortiz-Cuaran, Villejuif, FR 20 Focus on local treatment options Fiona McDonald, London, UK 11:00-12:30 Educational session Mesothelioma: New roads through understanding biology 20 Molecular targets: The basics Dean Fennell, Leicester, UK 20 Molecular targets: Clinical results Raffitt Hassan, Bethesda, MD, US 20 Immunotherapy: The basics Joachim Aerts, Rotterdam, NL 20 Immunotherapy: Clinical results Arnaud Scherpereel, Lille, FR 11:00-12:30 Educational session Immune checkpoint blockade: Basic mechanisms, preclinical evaluation and mechanisms of resistance 20 The basics of immunology in lung cancer Licia Rivoltini, Milan, IT 20 Genomic background and immune landscape Ferdinandos Skoulidis, Houston, TX, US 20 Cancer immunity and immune set point Daniel S. Chen, San Francisco, CA, US 20 Mechanisms of resistance to immune checkpoint blockade 12:30-13:00 Poster lunch Nathalie Bendriss Vermare, Lyon, FR 13:00-14:00 13:00-14:00 Industry Satellite Symposium 6 Industry Satellite Symposium 7 14:10-14:40 Keynote lecture Room B 30 Predictive biomarkers for immune checkpoints inhibitors 14:45-16:15 Multidisciplinary Tumour Board 30 Can we rely on liquid biopsy for treatment decision at the time of acquired resistance? 30 EGFR activating mutation plus exon 20 comutation at baseline: Which TKI should we select for frontline treatment? 30 Progression on osimertinib: When is it possible to continue with a targeted therapy? Chair: Olivier Michielin, Lausanne, Switzerland Jordi Remon-Masip, Barcelona, ES Federico Cappuzzo, Milan, IT David Planchard, Villejuif, FR 6

7 Friday, 13 April 2018 cont. 14:45-16:15 Educational session Less frequent driving alterations 20 MET Alexis Cortot, Lille, FR 20 BRAF Christian Rolfo, Antwerp, BE 20 RET and NTRK Robert C. Doebele, Aurora, CO, US 20 HER2 and others Enriqueta Felip, Barcelona, ES 16:15-16:45 Coffee break 16:45-18:15 Educational session How to prioritise the use of biomarkers 20 Clinical oncologist s perspective on biomarker James Chih-Hsin Yang, Taipei, TW testing by next generation sequencing 20 The value of circulating tumour DNA testing in Cécile Le Pechoux, Villejuif, FR radiotherapy 20 Lung cancer biomarkers relevant to thoracic Paul Van Schil, Edegem, BE surgery practice 20 Pathologist s challenges in biomarker testing Ming Tsao, Toronto, ON, CA 16:45-18:15 Room W 5 th ESO Lung Cancer Observatory Matti Aapro, Genolier, CH and Enriqueta Felip, Barcelona, ES 10 Tobacco control, strategies and figures: What s C. Adams, CH next? 10 Lung cancer screening in 2019? H. de Koning, NL 10 Early-stage NSCLC, next steps: Staging, surgery, molecular determinations 10 Radiation oncology: New approaches in 2019 F. Mornex, FR 10 What to ask your pathologist today and in 2019? K. Kerr, UK 10 Developments in immunotherapy: What practice changing studies will mature in 2019? 10 Developments in targeted therapies: What E. Felip, ES practice changing studies will mature in 2019? 10 The patient s perspective F. Johansson, SE 10 Panel discussion 18:40-19:40 18:40-19:40 Industry Satellite Symposium 8 Industry Satellite Symposium 9 Saturday, 14 April :45-09:15 Keynote lecture Chair: 30 Early detection of lung cancer Nir Peled, Tel Aviv, IL 7

8 09:20-10:50 Educational session New perspectives in the treatment of SCLC 20 Chemotherapy and SCLC: The past, the present Mary O Brien, Sutton, UK and also the future? 20 Radiotherapy: What is in place today and Umberto Ricardi, Turin, IT what might the future hold? 20 New targets in this "target orphan" disease Gregory J. Riely, New York, NY, US 20 The current role of immunotherapy and its place Leora Horn, Nashville, TN, US in the future 10:50-11:20 Coffee break 11:20-12:50 Educational session Non-small cell neuro-endocrine tumours 20 Diagnosis and pathology classification Andrew Nicholson, London, UK 20 Treatment of large cell neuro-endocrine carcinoma Anne-Marie Dingemans, Maastricht, NL 20 Staging and surgical treatment of carcinoids Mariano Garcia-Yuste, Valladolid, ES 20 Non-surgical treatment of carcinoids Angela Lamarca, Manchester, UK 12:50-13:00 Closing remarks 8

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES 10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture